Get the Stockscreener App
26.12
1.84%
-0.49
After Hours:
26.22
0.10
+0.38%
Moderna Inc stock is traded at $26.12, with a volume of 6.59M.
It is down -1.84% in the last 24 hours and down -19.73% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$26.61
Open:
$26.545
24h Volume:
6.59M
Relative Volume:
0.62
Market Cap:
$10.10B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.992
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-5.38%
1M Performance:
-19.73%
6M Performance:
-19.88%
1Y Performance:
-69.02%
1-Day Range:
$25.89
$26.88
1-Week Range:
$25.89
$28.60
52-Week Range:
$23.15
$91.99
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.12 | 10.39B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Is Moderna Inc. gaining market shareGame-Changing Investment Alerts - mustnews.co.kr
54,198 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by ABC Arbitrage SA - MarketBeat
Moderna, Inc. (MRNA)’s “Got The Double Whammy,” Says Jim Cramer - Yahoo Finance
Envestnet Asset Management Inc. Sells 12,212 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
IBM and Moderna have simulated the longest mRNA pattern without AI — they used a quantum computer instead - Live Science
LPL Financial LLC Grows Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
UTMB, Moderna hit with vaccine research cancellation month after publishing new mRNA data - The Business Journals
Moderna to Cut 10% of Staff to Offset Slowing Covid Business - MSN
OVERSEA CHINESE BANKING Corp Ltd Has $1.16 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
XTX Topco Ltd Purchases 27,237 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here? - Barchart.com
Is Moderna Stock A Sell After Cutting Its Sales Outlook — Again? - Investor's Business Daily
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Banco Santander S.A. - MarketBeat
Q3 Earnings Forecast for Moderna Issued By Leerink Partnrs - MarketBeat
Moors & Cabot Inc. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
RFK Jr. ends mRNA vaccine support; Moderna, other Mass. firms affected - WCVB
US HHS cancels 22 BARDA mRNA vaccine contracts - BioWorld MedTech
Public health experts dismayed by RFK Jr.'s defunding of mRNA vaccine research : ShotsHealth News - NPR
Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals - MSN
HHS abandons mRNA vaccine research - BioPharma Dive
US health agency to wind down mRNA vaccine development - Reuters
The intrapreneur edge: What we learned at Moderna about the need to act like a startup - The Globe and Mail
Robust Growth in Mrna Therapeutics Process Development Market - openPR.com
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - Amarillo Globe-News
RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA - BioSpace
HHS halts funding for mRNA vaccine activities (MRNA:NASDAQ) - Seeking Alpha
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga
Moderna Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Banque Cantonale Vaudoise Buys Shares of 14,589 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca - MSN
Moderna (NASDAQ:MRNA) Shares Gap DownHere's Why - MarketBeat
Wealthquest Corp Buys Shares of 36,587 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
US Health Department Pulls Back on Funding mRNA Vaccine Research - Bloomberg.com
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Milwaukee Journal Sentinel
Barclays Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Moderna: RSV Upside Slim, Cash Burn Heavy (NASDAQ:MRNA) - Seeking Alpha
July Layoffs Skyrocket 487% YOY With Merck Cuts - BioSpace
Let’s make a deal? Big Pharma execs express varying views on their M&A future - PharmaVoice
Cancer Vaccine Research Report 2025-2035 | Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships - Yahoo Finance
Zurcher Kantonalbank Zurich Cantonalbank Sells 134,443 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Holdings Cut by Pacer Advisors Inc. - MarketBeat
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates - El Paso Times
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Pocono Record
Moderna Seeks To Be Cleared In $5B COVID Vax Patent Case - Law360
BofA Securities lowers Moderna stock price target to $24 on COVID reliance - Investing.com
EU regulator backs Moderna's updated COVID vaccine - MSN
Moderna Tops Vaccine Expectations But Trims Future Outlook - Finimize
Moderna stock falls as UBS reiterates Buy rating amid cost cuts - Investing.com Canada
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):